{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-005457","form_type":"8-K","ticker":"CLDX","cik":"0000744218","company_name":"Celldex Therapeutics, Inc.","filed_at":"2022-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.066415+00:00","generated_at":"2026-06-24T03:05:21.857929+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Celldex Q2 net loss $0.77/sh; barzolvolimab Ph2 studies initiated; settles SRS litigation","bullets":["Net loss $36M ($0.77/sh) vs $13.4M ($0.34/sh) in Q2 2021; revenue $0.2M down from $3.5M.","Cash $356.8M at June 30; management says sufficient through 2025.","Barzolvolimab interim CSU: mean UAS7 reduction 66.6% (1.5mg/kg) and 75.1% (3mg/kg); Phase 2 studies dosed.","Settled Kolltan contingent milestones reduced from $172.5M to $80M; $15M paid in July; $6.3M remeasurement gain.","Deprioritized CDX-1140 program; focusing on barzolvolimab and bispecific platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-005457","json":"https://secwatch.observer/filing/0001171843-22-005457.json","markdown":"https://secwatch.observer/filing/0001171843-22-005457.md","text":"https://secwatch.observer/filing/0001171843-22-005457.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744218/000117184322005457/0001171843-22-005457-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744218/000117184322005457/f8k_080822.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T03:05:21.857929+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}